Restarting Tirzepatide (Zepbound) After Colonoscopy
Zepbound (tirzepatide) can generally be resumed the day after colonoscopy once oral intake is tolerated and there are no post-procedure complications requiring delay [1]. For once-weekly GLP-1/GIP agents, common endoscopy medication protocols specify resuming either the next day or the next scheduled dose, depending on local instructions and timing of the last dose [1].
Medication Restart Timing After Procedure
For once-weekly GLP-1 receptor agonists (including tirzepatide), restarting after colonoscopy is commonly permitted after the procedure when the patient is tolerating intake [1]. Protocols that hold tirzepatide before the procedure typically direct restarting either “next day” or “next scheduled dose” [1].
Sedation and Aspiration Risk Considerations
GLP-1/GIP agents are managed around sedation primarily due to concerns about delayed gastric emptying and aspiration risk [2]. The gastrointestinal multi-society approach emphasizes individualized peri-procedural management rather than universal stopping for all patients [2]. These peri-procedural considerations inform pre-procedure handling rather than a strict post-colonoscopy delay in all patients [2].
Practical Decision Framework
Resumption timing should follow the colonoscopy discharge instructions and the endoscopy unit’s medication guidance [1].
Common Clinical Scenarios
If the colonoscopy was uncomplicated and oral intake is resumed promptly, resumption the next day is commonly consistent with endoscopy medication protocols for once-weekly GLP-1/GIP therapy [1]. If the next scheduled weekly dose occurs the following day, resumption at the next scheduled dose is also consistent with protocol language [1].
When to Delay Restart
Restart should be delayed when there are post-procedure clinical reasons requiring delayed diet advancement or when the prescribing clinician or endoscopy team advises additional hold [1].